Related Experiment Videos
Metabolism of paracetamol in children with chronic liver disease
S S al-Obaidy1, P J McKiernan, A Li Wan Po
1School of Pharmacy, Queen's University of Belfast, Northern Ireland.
Insights
Single doses of paracetamol are safe for children with chronic liver disease. Metabolism studies show normal paracetamol sulphate formation and slightly increased glucuronide formation, with no significant concerns for use.
Area of Science:
- Pharmacology
- Hepatology
- Pediatrics
Background:
- Chronic liver disease in children can alter drug metabolism.
- Paracetamol (acetaminophen) is a common analgesic and antipyretic used in pediatric populations.
- Understanding paracetamol metabolism in pediatric liver disease is crucial for safe dosing.
Purpose of the Study:
- To investigate the metabolism of single paracetamol doses in pediatric patients with chronic liver disease.
- To assess the impact of liver disease severity on paracetamol pharmacokinetic parameters.
Main Methods:
- Study included thirteen pediatric patients (7 months to 12 years) with varying chronic liver disease severity.
- Analyzed paracetamol elimination half-life, serum albumin, and prothrombin time.
- Measured glucuronide and sulphate metabolite formation rates and urinary metabolite ratios.
Main Results:
- Paracetamol elimination half-life correlated negatively with serum albumin and positively with prothrombin time.
- Glucuronide formation rate constant was higher in children with liver disease compared to healthy controls.
- Paracetamol sulphate formation rate was not significantly different from healthy children.
Conclusions:
- Single-dose paracetamol administration appears safe in pediatric patients with chronic liver disease.
- Metabolic profile suggests no significant cause for concern with occasional paracetamol use in this population.
- Further studies with larger cohorts may be warranted to confirm findings.
Objective:
To study the metabolism of single doses of paracetamol in paediatric patients with chronic liver disease admitted to a hospital liver disease clinic.
Results:
Thirteen paediatric patients, aged 7 months to 12 years, with chronic liver disease of varying severity were studied. In these children, paracetamol elimination half-life was negatively correlated with serum albumin and positively with prothrombin time, as previously reported in adults with liver disease. The rate constant of glucuronide formation was higher in the children with liver disease compared to the value reported in healthy children of similar ages. The rate constant of the formation of paracetamol sulphate was no different from that in normal children. The 36 h urinary paracetamol glucuronide to sulphate ratio was 1.4 (95% CI 0.8 to 1.7). This mean ratio was higher than in healthy children (0.81 and 0.75) but not significantly so, probably because of a Type 1 error due to the inevitable small sample size arising from the nature of the population being studied.
Conclusion:
The present study provides reassuring additional data to indicate that, at least for single doses, there is no cause for concern in the use of paracetamol in children with chronic liver disease.